Biotech News

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences (IDYA)IDEAYA Biosciences2026-06-25 13:46 ESTClinical readout

IDYA (IDYA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is idya.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDYAIDEAYA Biosciences2026-06-25 13:46 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

View all latest news

IDEAYA Biosciences

IDEAYA Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

IDYAIDEAYA Biosciences2026-06-27 08:23 EST

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDYAIDEAYA Biosciences2026-06-27 08:23 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDYAIDEAYA Biosciences2026-06-27 08:23 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-27 08:23 EST

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDYAIDEAYA Biosciences2026-06-27 08:23 EST

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States